Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Intel: Peripheral Nerve Stim Players Edge Out Innovative Paths

Executive Summary

While demand for spinal cord stimulation (SCS) devices used in pain management continues to expand at double-digit rates, a small but growing number of highly innovative companies that develop stimulators to specifically target peripheral nerve pain is creating excitement among pain doctors looking for better options to treat an intractable population that's seen little success with standard therapy. With millions of people worldwide suffering from low back pain, severe headaches and migraines, neck pain and other chronic pain, the demand for safe, effective, percutaneously-placed devices remains high. In this article, we'll highlight emerging companies working on PNS devices and provide insights from pain physicians on the pros and cons of these devices.

You may also be interested in...



Pain Device Firm’s Undoing Over $16K ‘Piece of Plastic’

Neuromodulation company Stimwave has agreed to pay $10M in fines and the ex-CEO is facing health care fraud charges after a whistleblower revealed the company was selling a fraudulent “receiver” component. 

NANS 2020: Boston Scientific Expects Neuromodulation Business Rebound In 2020

At NANS, Boston Scientific presented results of the COMBO study, announced a partnership with IBM Research on digital health, and reported strong US growth in its deep brain stimulation business. Boston's C suite sees rebound for lagging neuromodulation business in 2020.

Abbott To Provide Devices To NIH’s BRAIN Initiative

Abbott has agreed to provide directional deep brain stimulation, spinal cord stimulation, and dorsal root ganglion therapy devices to help NIH study treatments for chronic pain and progressive movement disorders like Parkinson's disease.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel